Hypertension and concurrent arrhythmias

Current Pharmaceutical Design

Volumn 9, Issue 21, 2003, Pages 1703-1713

  Lombardi, Federico ^a   Terranova, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BENZTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; OXPRENOLOL; PRAZOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TISSUE LEVEL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RISK ASSESSMENT; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; T WAVE; TREATMENT PLANNING;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; ARRHYTHMIA; CALCIUM CHANNEL BLOCKERS; DEATH, SUDDEN, CARDIAC; DIURETICS; HUMANS; HYPERTENSION; RISK FACTORS; SYMPATHOLYTICS; TACHYCARDIA, SUPRAVENTRICULAR; TACHYCARDIA, VENTRICULAR;

EID: 0042490657     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454496     Document Type: Review

References (104)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-1022.
2. Messerli FH, Nunez BD, Nunez MM, Garavaglia GE, Schmieder RE, Ventura HO. Hypertension and sudden death. Disparate effects of calcium entry blockers and diuretic therapy on cardiac dysrhythmias. Arch Int Med 1989; 149: 1263-1267.
3. Kaplan NM. Systemic Hypertension: Mechanisms and Diagnosis. In: Heart Disease: Textbook of Cardiovascular Medicine. Braunwald E, Zipes D, Libby P. Eds. W.B. Saunders Company, 2001; pp. 941-971.
4. Melina D, Colivicchi F, Guerrera G, Melina G, Frustaci A, Caldarulo M, et al. Prevalence of left ventricular hypertrophy and cardiac arrhythmias in borderline hypertension. Am J Hypertens 1992; 5: 570-573.
5. Novo S, Barbagallo M, Abrignani MG, Nardi E, Di Maria GU, Longo B, et al. Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease. Am J Hypertens 1997; 10: 843-851.
6. Schoen FJ. Systemic. (left-sided) hypertensive heart disease. In Pathologic Basis of Disease, Cotran RS, Kumar V, Robbins SL, Eds. W.B. Saunders Company Philadelphia 1994; pp. 541-542.
7. Messerli FH, Glade LB, Elizardi DG, Dreslinski GR, Dunn FG, Frolich ED. Cardiac rhythm arterial pressure and urinary catecholamines in hypertension with and without left ventricular hypertrophy. Am J Cardiol 1981; 47: 480-487.
8. Messerli FH, Ventura HO, Elizardi DG, Dunn FH, Frolich ED. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984; 77: 18-22.
9. Messerli FH, Grodzicki T. Hypertension left ventricular hypertrophy ventricular arrhythmias and sudden death. Eur Heart J 1992; 13(Suppl. D): 66-69.
10. Luque-Otero M, Pérez Cascos F, Alcazar J. Increased ventricular arrhythmias in hypertension with left ventricular hypertrophy. J Hypertens 1986; 4(Suppl 6): 66-67.
11. Levy D, Anderson KM, Savane DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in hypertension with left ventricular hypertrophy. The Framingham Heart Study. Am J Cardiol 1987; 60 560-565.
12. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. N Engl J Med 1987; 317 787-792.
13. Siegel D, Cheitlin MD, Black DM, Seeley D, Hearst N, Hulley SB. Risk of ventricular arrhythmias in hypertensive men with left ventricular hypertrophy. Am J Cardiol 1990; 65 742-747.
14. Kostis JB, Lacy CR, Shindler DM, Borhani NO, Dallas Hall W, Wilson AC, et al. Frequency of ventricular ectopic activity in isolated systolic systemic hypertension. Am J Cardiol 1992; 69 557-559.
15. Schmieder RE, Messerli FH. Determinants of ventricular ectopy in hypertensive cardiac hypertrophy. Am Heart J 1992; 123 89-95.
16. Vester EG, Kuhls S, Ochinlet-Vester J, Vogt M, Straner BE. Electrophysiological and therapeutic implications of cardiac arrhythmias in hypertension. Eur Heart J 1992; 13(Suppl D): 70-81.
17. Ghali JK, Kadakia S, Cooper R, Liao Y. Impact of LVH on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991; 17 1277-1282.
18. Aronow WS, Epstein S, Koenogsberg M, Schwartz KS. Usefulness of echocardiographic LVH ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden cardiac death in elderly patients. Am J Cardiol 1988; 62 1124-1125.
19. Coste P, Clementy J, Besse P, Bricaud H. Left ventricular hypertrophy and ventricular dysrhythmia risk in hypertensive patients: evaluation by programmed electrical stimulation. J Hypertens 1988; 6(Suppl 4): 116-118.
20. Bringle SD, Dunn FG, McKillop JH, Lorimer AR, McFarland PW, Cobbe SM. How important are ventricular arrhythmias in hypertensive LVH? Eur Heart J 1989; 10(Suppl I): 200. (Abstr).
21. Kreger BE, Cupples A, Kannel WB. The electrocardiogram in prediction of sudden death: the Framingham Study experience. Am Heart J 1987; 113 377-382.
22. Salcedo EE, Marwick TH, Korzick DH, Goormastic M, Go RT. Left ventricular hypertrophy sensitizes the myocardium to the development of ischaemia. Eur Heart J 1990; 11 (Suppl G): 72-78.
23. Cosìn J, Hernàndiz A, Solaz J, Seguì J, Andrés F. Fisiopatologia cardiaca en la hypertension aguda. In. El Corazon en la Hipertension Arterial, Doyma SA, Diez J. Eds. Barcelona 1992; pp. 137-145.
24. Messerli FH, Kaesser UR, Josem CJ. Effects of antihypertensive therapy on hypertensive heart disease. Circulation 1989; 80(Suppl IV): 145-150.
25. Cerbai E, Zaza A, Mugelli A. Pharmacology of membrane ion channels in human myocites. In: Cardiac Electrophysiology: from cell to bedside. Zipes D, Jalife J. Eds. W.B. Saunders Company 2000; pp. 167-172.
26. Bozler E. The initiation of impulses in cardiac muscle. Am J Physiol 1943; 138 273-282.
27. Assayag P, Carré F, Chevalier B, Delcayre C, Mansier P, Swynghedaw B. Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype: I - fibrosis. Cardiovasc Res 1997; 34: 439-444.
28. 2+ handling and vunerability to ventricular fibrillation in spontaneously hypertensive rats. Hypertension 1997; 30: 461-467.
29. Spach MS, Miller WT, Geselowitz DB, Barr RC, Kootsey JM, Johnson EA. The discontinuous nature of propagation in normal canine cardiac muscle. Evidence of recurrent discontinuity of intracellular resistance that affects the membrane currents. Circ Res 1981; 48: 39-54.
30. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium-fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
31. Vester EG, Emschermann C, Stobbe U, Ochiulet-Vester J, Perings C, Kuhl U, et al. Late potentials and heart rate variability in heart muscle disease. Eur Heart J 1994; 15(Suppl C): 25-33.
32. Hennersdorf MG, Strauer BE. Arterial hypertension and cardiac arrhythmias. J Hypertens 2001; 19: 167-177.
33. Galinier M, Balanescu S, Fourcade J, Dorobantu M, Albenque JP, Massabuau P, et al. Prognostic value of arrhythmogenic markers in systemic hypertension. Eur Heart J 1997; 18: 1484-1491.
34. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart Rate Variability. Standards of measurement physiological interpretation and clinical use. Circulation 1996; 93: 1043-1065.
35. Algra A, Tijssen JGP, Roelandt JRTC, Pool J, Lubsen J. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 1993; 88: 180-185.
36. Lombardi F. Chaos theory heart rate variability and arrhythmic mortality. Circulation 2000; 101: 8-10.
37. Singh JP, Larson MG, Tsuji H, Evans JC, O'Donnell CJ, Levy D. Reduced heart rate variability and new-onset hypertension. Insight into pathogenesis of hypertension: the Framingham Heart Study. Hypertension 1999; 32: 293-297.
38. Chakko S, Mulintapang RF, Huikuri HV, Kessler KM, Materson BJ, Myerburg RJ. Alterations in heart rate variability and its circadian rhythm in hypertensive patients with left ventricular hypertrophy free of coronary artery disease. Am Heart J 1993; 126: 1364-1372.
39. Perkiomaki JS, Ikaheimo MJ, Pikkujamsa SM, Rantala A. Lilja M, Kesaniemi YA, et al. Dispersion of the QT interval and autonomic modulation of the heart rate in hypertensive men with and without left ventricular hypertrophy. Hypertension 1996; 28: 16-21.
40. Lombardi F Parati G. Cardiovascular and respiratory changes during sleep in normal and hypertensive subjects. Cardiovascular Res 2000; 45: 200-211.
41. Davey PP, Bateman J, Mulligan IP, Forfar C, Hart G. QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities. Br Heart J 1994; 71: 268-273.
42. Mayet J, Shahi M, McGrath K, Poulter NL, Sever PS, Foale RA, et al. Left ventricular hypertrophy and QT dispersion in hypertension. Hypertension 1996; 28: 791-796.
43. Ichkhan K, Molnar J, Somberg J. Relation of left ventricular mass and QT dispersion in patients with systematic hypertension. Am J Cardiol 1997; 79: 508-511.
44. Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, Cohen RJ. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med 1994;.330: 235-241.
45. Olsson G, Tuomilehto J, Berglund G, Elmfeld D, Warnold I, Barber H, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study. Am J Hypertens 1991; 4: 152-158.
46. Kohya T, Yokoshiki H, Tohse N, Kanno M, Nakaya H, Saito H, et al. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias: beneficial effects of angiotensin II blockade. Circ Res 1995; 76: 892-899.
47. Rials SJ, Wu Y, Ford N, Pauletto FJ, Abramson SV, Rubin AM, et al. Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability in inducible arrhythmia in feline heart. Circulation 1995; 91: 426-430.
48. Yokoshiki H, Kohya T, Tomita F, Tohse N, Nakaya H, Kanno M, et al. Restoration of action potential duration and transient outward current by regression of left ventricular hypertrophy. J Mol Cell Cardiol 1997; 29: 1331-1339.
49. Bennett WM, McDonald WJ, Kuehnel E, Hartnett MN, Porter GA. Do diuretics have antihypertensive properties indipendent of natriuresis? Clin Pharmacol Ther 1977; 22: 499-504.
50. Freis ED. How diuretics lower blood pressure. Am Heart J 1983; 106: 185-187.
51. Kaplan NM. Systemic Hypertension: Therapy. In: Heart Disease: Textbook of Cardiovascular Medicine. Braunwald E, Zipes D, Libby P. Eds. W.B. Saunder Company, 2001; pp. 972-991.
52. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program. (SHEP). JAMA 1991; 265(24): 3255-3264.
53. Dalhöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
54. Siskovick DS, Raghunathan TE, Psaty BM, Hoepsell TD, Wicklund KG, Lin X, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852-1857.
55. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 1982; 248: 1465-1477.
56. Curtis MJ, Hearse DJ. Ischaemia-induced and reperfusion-induced arrhythmias differ in their sensitivity to potassium: implication for mechanisms of initiation and manteinance of ventricular fibrillation. J Mol Cell Cardiol 1989; 21: 21-40.
57. Yano K, Hirata M, Matsumoto Y, Hano O, Mori M, Ahmed R, et al. Effects of chronic hypokaliemia on ventricular vulnerability during acute myocardial ischaemia in the dog. Jpn Heart J 1989; 30: 205-217.
58. Frishman WH Hershman D. Beta adrenoreceptor blockers. In: Cardiovascular Drug Therapy. Messerli FH Ed. W.B. Saunders, 1996; pp. 465-601.
59. Psaty BM, Koepsell TD, LoGerfo JP, Wagner EH, Inui TS. 1989; β-blockers and the primary prevention of coronary heart disease in patients with high blood pressure. JAMA 261: 2087-2094.
60. Fletcher A, Beevers DG, Bulpitt C, Butler A, Coles AC, Hunt D, et al. Beta-adrenoreceptor blockade is associated with increased survival in male but not in female hypertensive patients, a report from the DHSS Hypertension Care Computing Project. (DHCCP). J Hum Hypertens 1988; 2: 219-227.
61. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenol: the International Primary Prevention Study ib Hypertension. (IPPPSH) J Hypertens 1985; 3: 379-392.
62. Wilhelmsen L, Berglund G, Elmfeld D. Beta-blockers versus diuretics in hypertensive men: main results from HAPPHY trial. J Hypertens 1987; 5: 561-572.
63. Wikstrand J, Warnold I, Olsson G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988; 259: 1976-1982.
64. Olsson G, Tuomilehto J, Berglund G. Primary prevention of sudden cardiovascular death in hypertensive patients: mortality results from the MAPHY Study. Am J Hypertens 1991; 4: 151-158.
65. Coope J. Hypertension in the elderly. J Hypertens 1987; 5(Suppl. 3): S69-S72.
66. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986; 293: 1145-1151.
67. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
68. Page I, Bumpus F. Angiotensin. In Handbuch der Experimentelle Pharmakologie. Spinger V. (Eds) Berlin 1974; Vol. 37.
69. Testa MA, Anderson RB, Nackley JF, Hollenberg NK and the Quality-of-Life Hypertension Study Group. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. N Engl J Med 1993; 328: 907-913.
70. Keilani T, Schlueter W, Batlle D. Selected aspects of ACE inhibitor therapy for patients with renal disease: effects on proteinuria lipids and potassium. J Clin Pharmacol 1995; 35: 87-97.
71. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failue during treatment with enalapril. (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992; 70(4): 479-487.
72. Knight EL, Glynn RJ, McIntryre KM, Mogun H, Avorn J. Predictor of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction. (SOLVD). Am Heart J 1999; 138(5 Pt 1): 801-803.
73. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5(3): 178-187.
74. Hager WD, Davis BR, Riba A, Moye LA, Wun CC, Rouleau JL, et al. Absence of deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE investigators. Survival and Ventricular Enlargement. Am Heart J 1998; 135(3): 406-413.
75. Bonarjee VV, Omland T, Nilsen DW, Cartensen S, Berning J, Edner M, et al. Left ventricular volumes ejection fraction and plasma proatrial natriuretic factor. (1-98) after withdrawal of enalapril treatment initiated early after myocardial infarction. CONSENSUS II Multi-Echo Study Group. Br Heart J 1995; 73(6): 506-510.
76. Spargias K, Ball S, Hall A. The prognostic significance of history of systemic hypertension in patients randomized to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy. J Hum Hypertens 1999; 13(8): 511-516.
77. Avanzini F, Ferrario G, Santoro L, Peci P, Giani P, Santoro E, et al. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico-3 Investigators. Risks and benefits of early treatment of acute myocardial infarction with an angiotensin-converting enzyme inhibitor in patients with a history of arterial hypertension: analysis of the GISSI-3 database. Am Heart J 2002; 144(6): 1018-1025.
78. Boutitie F Boissel JP Connolly SJ Camm AJ,Cairns JA Julian DG. Amiodaroene interaction with beta-blockers: analysis of the merged EMIAT and CAMIAT databases. Circulation 1999; 99: 2268-2275.
79. Pedersen OD Bagger H Kober L. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 1999; 100: 376-380.
80. ALLHAT Authors. Major outcome in high risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-2997.
81. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
82. Devereux RB, Palmieri V, Liu JE, Watchell K, Bella JN, Boman K, et al. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention for Endpoint Reduction study. Journal of Hypertension 2002; 20: 1445-1450.
83. Devereux RB, Palmieri V, Liu JE, Watchell K, Bella JN, Boman K, et al. Cardiovascular morbidity and mortality in patients without pre-existing vascular disease in the Losartan Intervention For Endpoint Reduction in Hypertension Study. Circulation 2002; 106: II475.
84. Kohlhardt M, Fleckenstein A. inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 1977; 298: 267-272.
85. Nishimura RA, Schwartz RS, Holmes DR Jr, Tajic AJ. Failure of calcium channels blockers to improve ventricular relaxation in humans. J Am Coll Cardiol 1993; 21: 182-188.
86. Staessen JA, Fagard R, Thijs L. Randomised double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe. (Syst-Eur) Trial Investigator. Lancet 1977; 350: 757-764.
87. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitor calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials: Blood Pressure Lowering Treatment Trailists' Collaboration. Lancet 2000; 356: 1955-1964.
88. ALLHAT Authors. Major cardiovascular events in hypertensive patients randomised to doxazosin vs chlorthalidone. JAMA 2000; 283: 1967-1975.
89. Oates JA, Gillespie L, Udenfriend S, Sjoerdsma A. Decarboxylase inhibition and blood pressure reduction by α-methyl-3,4-dihydroxy-DL-phenylalanine. Science 1960; 131: 1890-1891.
90. Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE. Reversal of left ventricular hypertrophy in hypertensive patients with methyldopa, lack of association with blood pressure control. Am J Cardiol 1982; 49: 795-801.
91. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
92. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weismann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40(6): 892-896.
93. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol. (Oxf) 2002; 57(4): 457-465.
94. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161(5): 1773-1781.
95. Tostes RC, Touyz RM, He G, Chen X, Schiffrin EL. Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clin Sci (Lond) 2002; 130(Suppl 48): 25S-30S.
96. Rahmouni K, Sibug RM, De Kloet ER, Barthelmebs M, Grima M, Imbs JL, et al. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal function in DOCA-salt hypertension. Eur J Pharmacol 2002; 436(3): 207-216.
97. Pereira LM, Mandarim-de-Lacerda CA. Myocardial changes after spironolactone in spontaneously hypertensive rats. A laser scanning confocal microscopy study. J Cell Mol Med 2002; 6(1): 49-57.
98. Yalcin AU, Dincer M, Aslan V, Gulbas Z. Effects of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 2002; 24(4): 260-264.
99. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002; 25(6): 837-842.
100. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation 2002; 106 920-926.
101. Campese VM, Lasseter KC, Ferrario CM. Omapratilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 2001; 38, 1342-1348.
102. Danielsson BR, Skold AC, Azarbayjani F. Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Curr Pharm Des 2001; 7(9): 787-802.
103. Iyer S, Lahana R, Buelow R. Rational design and development of RDP58. Curr Pharm Des 2002; 8(24): 2217-29.
104. Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharm Des 2002; 8(3): 155-66.